Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
29 12 2022
29 12 2022
Historique:
accepted:
06
09
2022
received:
01
06
2022
pubmed:
21
9
2022
medline:
3
1
2023
entrez:
20
9
2022
Statut:
ppublish
Résumé
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and breakthrough COVID-19 between January 2021 and March 2022 were analyzed. A total of 1548 cases were included, mainly lymphoid malignancies (1181 cases, 76%). After viral sequencing in 753 cases (49%), the Omicron variant was prevalent (517, 68.7%). Most of the patients received ≤2 vaccine doses before COVID-19 (1419, 91%), mostly mRNA-based (1377, 89%). Overall, 906 patients (59%) received COVID-19-specific treatment. After 30-day follow-up from COVID-19 diagnosis, 143 patients (9%) died. The mortality rate in patients with the Omicron variant was 7.9%, comparable to other variants, with a significantly lower 30-day mortality rate than in the prevaccine era (31%). In the univariable analysis, older age (P < .001), active HM (P < .001), and severe and critical COVID-19 (P = .007 and P < .001, respectively) were associated with mortality. Conversely, patients receiving monoclonal antibodies, even for severe or critical COVID-19, had a lower mortality rate (P < .001). In the multivariable model, older age, active disease, critical COVID-19, and 2-3 comorbidities were correlated with a higher mortality, whereas monoclonal antibody administration, alone (P < .001) or combined with antivirals (P = .009), was protective. Although mortality is significantly lower than in the prevaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality. Death rate was lower in patients who received monoclonal antibodies, alone or in combination with antivirals.
Identifiants
pubmed: 36126318
pii: S0006-4971(22)01301-5
doi: 10.1182/blood.2022017257
pmc: PMC9492383
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antiviral Agents
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2773-2787Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 by The American Society of Hematology.
Références
Blood Adv. 2020 Dec 8;4(23):5966-5975
pubmed: 33278301
Br J Haematol. 2021 Sep;194(6):999-1006
pubmed: 34085278
Blood. 2021 Sep 2;138(9):811-814
pubmed: 34189565
Leukemia. 2021 Dec;35(12):3573-3577
pubmed: 34023850
Br J Haematol. 2022 Feb;196(3):548-558
pubmed: 34649298
Leukemia. 2022 Feb;36(2):588-590
pubmed: 34545184
J Clin Oncol. 2022 May 1;40(13):1414-1427
pubmed: 35286152
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Hemasphere. 2021 Jun 25;5(7):e612
pubmed: 34235404
Leukemia. 2022 Jun;36(6):1467-1480
pubmed: 35488021
J Hematol Oncol. 2021 Oct 14;14(1):168
pubmed: 34649563
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Blood Adv. 2021 Aug 24;5(16):3053-3061
pubmed: 34387648
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Blood Rev. 2022 Jul;54:100931
pubmed: 35120771
Am J Hematol. 2022 Aug;97(8):E321-E324
pubmed: 35702859
Lancet. 2022 Feb 12;399(10325):665-676
pubmed: 35151397
Blood. 2022 Mar 10;139(10):1439-1451
pubmed: 34662390
Lancet Oncol. 2022 Jun;23(6):748-757
pubmed: 35617989
Clin Infect Dis. 2022 May 3;74(9):1515-1524
pubmed: 34358310
Eur J Cancer. 2022 Apr;165:184-194
pubmed: 35248840
Br J Haematol. 2022 May;197(3):302-305
pubmed: 35076937
MMWR Morb Mortal Wkly Rep. 2021 Aug 06;70(31):1059-1062
pubmed: 34351882
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
Am J Hematol. 2021 Oct 1;96(10):1195-1203
pubmed: 34185336
J Hematol Oncol. 2021 Jul 29;14(1):119
pubmed: 34325728
Am J Pathol. 2022 Apr;192(4):642-652
pubmed: 35123975
Cancer Cell. 2021 Oct 11;39(10):1297-1299
pubmed: 34509182
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176
pubmed: 34437525
Blood. 2022 Aug 4;140(5):445-450
pubmed: 35588468
Ann Hematol. 2022 Aug;101(8):1877-1878
pubmed: 35391563
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Ann Oncol. 2022 Mar;33(3):340-346
pubmed: 34958894
JAMA Oncol. 2022 Jul 1;8(7):1027-1034
pubmed: 35394485
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
Blood. 2022 Mar 10;139(10):1588-1592
pubmed: 34748627
Lancet Haematol. 2020 Oct;7(10):e737-e745
pubmed: 32798473
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246